NCT01566279View on ClinicalTrials.gov

A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Everolimus

All patients will receive everolimus 10mg q.d.

Trial Locations (3)

1066 CX

NKI-AVL, Amsterdam

3075 EA

Erasmus Medical Center, Rotterdam

3584 CX

University Medical Center Utrecht, Utrecht

All Listed Sponsors
lead

UMC Utrecht

OTHER

NCT01566279 - A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03) | Biotech Hunter | Biotech Hunter